Efficient and stable delivery system of antisense oligonucleotide (ASO) is important and urgently needed. Here, an ASO delivery system, Lp-PPRP, which contains a cationic polymer based on PEI (branched, 25 kDa), named PEI-PC and a palmitic acid modified R8 (R8-PA) was prepared to deliver a kind of ASO, LOR-2501. The characteristics of the nanoparticles and the cellular uptake of LOR-2501 in HeLa cells and A549 cells were studied. Lp-PPRP showed suitable particle size and zeta potential to combine with LOR-2501; the particle size and zeta potential of Lp-PPRP/LOR were 276.87 ± 5.63 nm and 18.03 ± 0.25 mV. experiments suggested that Lp-PPRP had lower cytotoxic and higher transfection efficiency for delivering LOR-2501 compared with PEI. The addition of PEI-PC and R8-PA contributed to enhance the transfection efficiency of the nanoparticles. In HeLa cells and A549 cells, Lp-PPRP could transport LOR-2501 and down-regulate the level of R1 protein efficiently, and the R1 down regulations were 64.56% and 66.34%, respectively. Results suggested potential utility of Lp-PPRP in the development of ASO in tumor therapy.
J Cell Physiol. 2019 Nov;234(11):20634-20647
[PMID:
31012113]
Medicine (Baltimore). 2018 Aug;97(33):e11916
[PMID:
30113492]
Mol Pharm. 2019 Jun 3;16(6):2265-2277
[PMID:
31063396]
Chem Commun (Camb). 2018 Feb 11;54(12):1489-1492
[PMID:
29359766]
ACS Appl Mater Interfaces. 2016 Oct 12;8(40):26613-26621
[PMID:
27617513]
Onco Targets Ther. 2014 Nov 03;7:2035-42
[PMID:
25395862]
Chem Sci. 2017 Dec 6;9(5):1112-1118
[PMID:
29629168]
Biomater Sci. 2016 Mar;4(3):494-510
[PMID:
26783563]
Bioconjug Chem. 2017 Mar 15;28(3):782-792
[PMID:
28209057]
Anticancer Res. 2019 Apr;39(4):1785-1793
[PMID:
30952718]
ACS Appl Mater Interfaces. 2018 Oct 17;10(41):34954-34964
[PMID:
30234287]
Drug Deliv. 2019 Dec;26(1):443-458
[PMID:
30929529]
Colloids Surf B Biointerfaces. 2015 Nov 1;135:274-82
[PMID:
26263216]
Drug Deliv. 2018 Nov;25(1):1996-2006
[PMID:
30799658]
Drug Deliv. 2016 May;23(4):1194-203
[PMID:
26635185]
Drug Deliv. 2018 Nov;25(1):122-131
[PMID:
29265887]
Peptides. 2018 Jun;104:62-69
[PMID:
29684592]
Drug Deliv. 2017 Nov;24(1):952-961
[PMID:
28633548]
Int J Pharm. 2015 Nov 10;495(1):527-535
[PMID:
26386137]
Drug Deliv. 2018 Nov;25(1):226-240
[PMID:
29313393]
Nanoscale. 2014 Aug 21;6(16):9742-51
[PMID:
25003978]
Oncogene. 2019 May;38(19):3696-3709
[PMID:
30664691]
Biomed Res Int. 2013;2013:710502
[PMID:
23862153]
Pharm Res. 2017 Feb;34(2):310-320
[PMID:
27896589]
Drug Deliv. 2017 Nov;24(1):1537-1548
[PMID:
28994324]
Artif Cells Nanomed Biotechnol. 2017 Dec;45(8):1685-1698
[PMID:
28278583]
J Control Release. 2006 May 15;112(2):229-39
[PMID:
16545478]
Int J Pharm. 2015 Apr 30;484(1-2):44-50
[PMID:
25698089]
J Control Release. 2007 Jun 22;119(3):360-7
[PMID:
17478000]
Methods Mol Biol. 2018;1828:91-124
[PMID:
30171537]
A549 Cells
Cell Line, Tumor
Cell Survival
Cell-Penetrating Peptides
Down-Regulation
HeLa Cells
Humans
Lipids
Nanoparticles
Oligonucleotides, Antisense
Particle Size
Polyethyleneimine
Transfection
Cell-Penetrating Peptides
Lipids
Oligonucleotides, Antisense
Polyethyleneimine
